Todays approval is another demonstration of what the FDA can accomplish when we try bold new things. The higher-dose GLP-1 is indicated to reduce excess body weight and maintain weight reduction long-term in adults with obesity, or overweight with at least one weight-related condition, per the FDAs statement
In fact, clinical weight loss trials with tirzepatide monotherapy show 2022% body weight reduction over 68 weeksresults that rival or exceed most multi-agent protocols reported in the literature
Who Qualifies for Medicare Coverage of Wegovy or Zepbound

Key points Diabetes impacts about 37 million people in the United States, approximately 11.3% of the population Type 2 diabetes accounts for up to 95% of people with diabetes GLP-1 medications are also known as glucagon-like peptide-1 (GLP-1) agonists, GLP-1 receptor agonists, incretin memetics, or GLP-1 analogs GLP-1 medications lower blood sugars by binding and activating the GLP-1 receptors to enhance insulin secretion and synthesis from the pancreas by promoting beta cells, suppressing glucagon secretion, slowing gastric emptying, and reducing food intake by decreasing appetite GLP-1 medications used in combination with exercise can synergistically work together to lower blood sugar levels GLP-1 agonists, specifically dulaglutide, semaglutide, and liraglutide, have demonstrated cardiovascular reduction benefits based on large clinical trials Virtual care and questions about GLP-1 medications If you have type 2 diabetes and want to learn more about GLP-1 medications, consider speaking with a healthcare provider

Taubes also praised Reynolds and Devine for sustaining the event year after year
But sometimes